Do Analysts Think Diversified Healthcare Trust (DHC) Is Still Worth Buying In 2024?

Diversified Healthcare Trust (NASDAQ:DHC) does about 901.74K shares in volume on a normal day but saw 784588 shares change hands in the recent trading day. The company now has a market cap of 757.98M USD. Its current market price is $3.15, marking a decrease of -2.17% compared to the previous close of $3.22. The 52 week high reached by this stock is $3.96 whilst the lowest price level in 52 weeks is $1.68.

Diversified Healthcare Trust (DHC) has a 20-day trading average at $2.91 and the current price is -20.45% off the 52-week high compared with 86.94% distance from its 52-week low. The 50-day simple moving average of the closing price is $2.64 and its 200-day simple moving average is $2.58. If we look at the stock’s price movements over the week, volatility stands at 4.65%, which increases to 5.64% over 1 month. It is also key to look at other market indicators of price movement for the stock, where we see that the relative strength index (RSI) is at 63.68 to suggest the stock is neutral.

The consensus objective for the share price is $5.00, suggesting that the stock has a potential upside of 37.0% over the period.

0 analysts have rated it as a buy and 0 have advised that investors hold their positions. The consensus recommendation rating is Strong Sell and Wall Street’s advice is for investors to Moderate Buy the stock.

The company shares received a number of brokerage firm price updates over the past month, with the latest being on December 10, 2020 when Wells Fargo downgraded the stock to “Underweight” and issued a price target of $4. Wells Fargo downgraded its price target at $9.

Diversified Healthcare Trust (DHC) stock is up 4.65% over the week and 7.51% over the past month. Its price is -15.78% year-to-date and 29.10% over the past year.

The stock last released its quarterly earnings report for quarter ended 3/31/2024, with the company’s earnings per share (EPS) of -0.22 above consensus estimates by 0.01. The company’s next earnings report forecasts estimating quarterly EPS at -0.28 and -1.14 for whole year. Expected sales for next quarter are $383.33M, which analysts say will come at $1.52B for the current fiscal year and next year at $1.66B. In addition, estimates put the company’s current quarterly revenue at an average of $372.13M.

To reach the target analysts have set, the stock logically needs to grow 37.0 percent from here.

The company has a return on investment of -6.40% and return on equity of -13.54%. The beta has a value of 2.19. Price to book ratio is 0.34 and price to sales ratio is 0.53.